Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Heart Failure | Unmet Need | Chronic Heart Failure | US/FR/DE/UK | 2021

Login to access report north_east
Contact sales account_box

Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure (CHF) cases, but proven pharmacological treatment options are limited. In February 2021, the FDA approved Entresto, an angiotensin receptor-neprilysin inhibitor (ARNI) marketed by Novartis for HFpEF, making it the first approved therapy for this subpopulation. Despite a long list of clinical trial failures, the HFpEF pipeline has some promising candidates, such as sodium-glucose cotransporter-2 (SGLT-2) inhibitors and mineralocorticoid receptor antagonists (MRAs). Substantial market opportunity remains for effective therapies to treat this heterogeneous and highly prevalent population.

QUESTIONS ANSWERED

  • Which drug attributes are the most influential in driving cardiologists’ prescribing decisions?
  • Which therapies used in the treatment of HFpEF do cardiologists perceive as performing the best on efficacy, safety and tolerability, and convenience of administration attributes?
  • What are the major areas of opportunity for drug developers in HFpEF treatment, and what is their likelihood of being fulfilled in the near future?
  • What are the trade-offs that surveyed cardiologists are willing to make across key attributes when considering new treatments for HFpEF?

PRODUCT DESCRIPTION

Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European cardiologists fielded in March 2021.

Key companies: Novartis, Pfizer

Key drugs: ACE inhibitors, ARBs, ARNIs (Entresto, sacubitril / valsartan), beta blockers, calcium channel blockers, diuretics, MRAs

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Multiple Myeloma – Current Treatment – Current Treatment: Physician Insights – Multiple Myeloma (US)
Multiple myeloma represents a complex and increasingly competitive hematologic malignancy landscape, with treatment approaches evolving rapidly across lines of therapy. While IMiDs, proteasome…
north_east
Report
Multiple Myeloma – Current Treatment – Treatment Sequencing – Multiple Myeloma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Epilepsy – Unmet Need – Unmet Need – Dravet Syndrome (US/EU)
Dravet syndrome (DS) is a rare, severe, pediatric-onset genetic epileptic encephalopathy that typically emerges within the first year of life and is marked by developmental delays and multiple…
north_east
Report
Alzheimer’s Disease – Unmet Need – Unmet Need – Agitation in Alzheimer’s Disease (US/EU)
Agitation affects most Alzheimer’s disease (AD) patients and comprises a constellation of disruptive symptoms for patients and their families, which may contribute to nursing home placement…
north_east
Report
Breast Cancer – Unmet Need – Unmet Need – Metastatic HR-Positive / HER2-Negative Breast Cancer (US/EU)
The landscape of advanced HR-positive / HER2-negative breast cancer treatment is continually evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio)…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east